Novel Therapeutic Formulations
Comparison of conventional
formulation and DRDO formulation (top)
respiratory formulations, only five per cent of the inhaled drug penetrates to
the depths in the lung towards the alveoli. The therapeutic effect on the lungs
is therefore limited. For this reason, only a few respiratory formulations of
salbutamol and steroids have been developed though a number of diseases afflict
the alveoli. DRDO has taken an early initiative in the field and has developed
five novel respiratory formulations. These include beta-agonists and nitric
oxide donor drugs that release nitric oxide at the site of action (alveoli).
Using scintigraphy, their deep penetration into the lungs (5 to 15 times more
than the conventional methods) has been confirmed. Their therapeutic benefit has
also been confirmed in human beings as a part of zero-phase human trial ahead of
regular clinical trials. Their utility has been shown in cases with pulmonary
hypertension (reduction in pulmonary blood pressure by 20 to 40 per cent as
measured by ECHO), in increasing oxygen transfer to the blood (in hypoxic
hypoxemia), in improvement of lung perfusion and in reducing cardio-pulmonary
stress. Enhancement in blood oxygen and lung perfusion was confirmed by pulse-oximetry
and lung perfusion scintigraphy, respectively.
Circulation in left hand doubles after NTG ointment application
DRDO has developed the
concept of treating peripheral vasculopathies using locally administered
vasodilators. Nuclear medicine methods have helped to confirm and quantify the
vasodilator action in human. Salbutamol and nitroglycerine ointments produced by
DRDO have now entered Phase II human trial after regulatory clearance.
Government of Himachal Pradesh is partnering DRDO in this collaborative venture.
The product will be useful in mild cold injuries and diabetic/ age-related